Medical Devices & Drug Device Combination Advisory

How we work

ASSESS

We establish a clear foundation before decisions become costly. This includes clarifying objectives, constraints, stakeholder expectations, and early risks across drug, device, quality, regulatory, and commercial perspectives.

Focus: clarity, alignment, and early risk control

DESIGN

We translate strategy into a compliant and executable development pathway. KAHLITY acts as an interface between pharmaceutical organisations, device developers, and CDMOs, coordinating cross-functional inputs and defining a defensible design approach.

Focus: alignment, feasibility, and regulatory realism

CREATE

We support controlled and efficient product development. We help maintain momentum across internal teams and external partners, supporting decision-making when trade-offs arise between speed, cost, and compliance.

Focus: progress without loss of control

VALIDATE

We ensure performance can be demonstrated and defended. Verification and validation activities are planned, risk-based, and aligned with intended use, claims, and regulatory expectations.

Focus: confidence, robustness, and defensibility

IMPLEMENT

We embed the solution into the organisation and regulatory landscape. This includes regulatory approval support, integration into Quality systems, and knowledge transfer to ensure sustainable operation across the product lifecycle.

Focus: approval, ownership, and long-term operability

Why this matters for Medical Device Products

Medical device development is increasingly complex, because it is driven by evolving regulations, heightened scrutiny from Notified Bodies, and pressure to move faster with fewer resources. Medical device programmes often fail or stall not because the technology is flawed, but because:

​

• Regulatory expectations are addressed too late

• Design decisions are made without full visibility of downstream impact

• Development activities drift out of alignment across functions.

​

KAHLITY’s role is to:

​

• Embed regulatory and quality thinking early, where it reduces rework and delays

• Align design, risk management, usability, and regulatory strategy early in the development lifecycle

• Support informed decision-making as requirements evolve

• Deliver devices that are ready for approval, inspection, and scale

Why this matters for Drug-Device Combination Products

Drug–device combination products rarely fail due to lack of expertise. They fail because interfaces are poorly managed. KAHLITY’s role is to:

​

• Bridge pharmaceutical and device cultures

• Align stakeholders around a single, coherent pathway

• Reduce friction, rework, and late-stage surprises

• Deliver compliant products without sacrificing efficiency or speed